➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
Boehringer Ingelheim
Moodys
Harvard Business School

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DALTEPARIN SODIUM

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Dalteparin Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00245856 Treatment of Upper Extremity Deep-Vein Thrombosis Completed Pfizer Phase 4 2002-09-01 The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
NCT00245856 Treatment of Upper Extremity Deep-Vein Thrombosis Completed University of Oklahoma Phase 4 2002-09-01 The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
NCT00264381 Management of Superficial Thrombophlebitis Completed Pfizer Phase 4 2002-10-01 The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
NCT00264381 Management of Superficial Thrombophlebitis Completed University of Oklahoma Phase 4 2002-10-01 The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
NCT00655122 Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study Terminated Pfizer Phase 4 2003-04-01 The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects. The secondary objective was a pharmacoeconomic evaluation of hromboprophylaxis with dalteparin sodium in primary care medical subjects.
NCT00942968 Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer Completed Eisai Inc. Phase 4 2009-06-01 The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dalteparin Sodium

Condition Name

Condition Name for Dalteparin Sodium
Intervention Trials
Venous Thromboembolism 5
Lower Extremity Superficial Thrombophlebitis 1
Stage I Multiple Myeloma 1
Aspirin 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dalteparin Sodium
Intervention Trials
Venous Thromboembolism 6
Thromboembolism 6
Thrombosis 4
Venous Thrombosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dalteparin Sodium

Trials by Country

Trials by Country for Dalteparin Sodium
Location Trials
United States 36
Canada 22
Spain 2
Netherlands 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dalteparin Sodium
Location Trials
District of Columbia 3
Kentucky 2
Florida 2
California 2
Oklahoma 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dalteparin Sodium

Clinical Trial Phase

Clinical Trial Phase for Dalteparin Sodium
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dalteparin Sodium
Clinical Trial Phase Trials
Completed 9
Terminated 2
Enrolling by invitation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dalteparin Sodium

Sponsor Name

Sponsor Name for Dalteparin Sodium
Sponsor Trials
Pfizer 6
Eisai Inc. 2
University of Oklahoma 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dalteparin Sodium
Sponsor Trials
Other 12
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Medtronic
Boehringer Ingelheim
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.